| Popis: |
Past two decades have witnessed a rapid progress in medical therapy for ulcerative colitis (UC), particularly availability and wide application of antitumor necrosis factor and anti-integrin biological agents for the treatment of moderate-to-severe UC. While corticosteroids are used as induction agents and immunomodulators are administered as maintenance agents, the biological agents have been applied for both induction and maintenance therapy. For mild UC, mesalamine agents, which carry a favorable safety profile, are routinely used for both induction and maintenance therapy. In addition to the conventional therapy, a variety of “alternative” agents have been explored and used for the treatment of mild, moderate, or severe UC, including calcineurin inhibitors, nicotine, probiotics, antibiotics, and fecal microbiota transplantation. In addition, a list of small molecule, pathway-targeted agents are being investigated. |
